专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180125818A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA 审中-公开
公开(公告)号：US20180125818A1
公开(公告)日：2018-05-10
申请号：US15629314
申请日：2017-06-21
申请人： The Johns Hopkins University
发明人： Michela Gallagher
IPC分类号： A61K31/4015 , A61K31/5513 , A61K45/06 , A61K31/407 , A61K31/454 , A61K31/20 , A61K31/554 , A61K31/519 , A61K31/496
CPC分类号： A61K31/4015 , A61K31/20 , A61K31/407 , A61K31/454 , A61K31/496 , A61K31/519 , A61K31/5513 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).

2. 发明申请

US20150094352A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION 审中-公开
标题翻译：改进认知功能的方法和组合
公开(公告)号：US20150094352A1
公开(公告)日：2015-04-02
申请号：US14261962
申请日：2014-04-25
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： Michela Gallagher , Rebecca Haberman , Ming Teng Koh
IPC分类号： A61K31/4015
CPC分类号： A61K31/4015 , A61K31/19 , A61K31/20 , A61K2300/00
摘要： This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).
摘要翻译：本发明涉及治疗年龄相关的认知障碍。本发明特别涉及突触小泡蛋白2A（SV2A）的抑制剂，如左乙拉西坦，西洛西坦和布立西坦，用于改善患有年龄相关认知障碍或处于危险中的受试者的认知功能，包括没有限制，具有轻度认知障碍（MCI）或年龄相关认知衰退（ARCD）或年龄相关记忆障碍（AAMI）风险的受试者。

3. 发明公开

US20240238246A1 METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS 审中-公开
公开(公告)号：US20240238246A1
公开(公告)日：2024-07-18
申请号：US18411753
申请日：2024-01-12
申请人： AGENEBIO, INC. , The Johns Hopkins University
发明人： Richard Mohs , Michela Gallagher , Arnold Bakker
IPC分类号： A61K31/4015 , A61K9/20 , A61P25/28
CPC分类号： A61K31/4015 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61P25/28
摘要： Methods for preventing or slowing the progression of cognitive impairment or preventing the development or reducing the rate of cognitive decline. Methods for slowing the volumetric atrophy or reduction of a subregion of the medial temporal lobe. Methods for slowing the volumetric atrophy or reduction of the entorhinal cortex (ERC). Methods for slowing the volumetric atrophy or reduction of the transentorhinal cortex (BA35). The methods comprise administering to an APOE4 non-carrier subject one or more of levetiracetam, brivaracetam or seletracetam, or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising levetiracetam, brivaracetam or seletracetam or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

4. 发明申请

US20210244709A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION 有权
公开(公告)号：US20210244709A1
公开(公告)日：2021-08-12
申请号：US17020196
申请日：2020-09-14
申请人： The Johns Hopkins University
发明人： Michela Gallagher , Rebecca Haberman , Ming Teng Koh , Arnold Bakker
IPC分类号： A61K31/4015 , A61P25/28 , A61K31/19 , A61K45/06 , A61B5/00 , C12Q1/6883 , G01N33/68 , G01N33/74 , G09B3/06
摘要： This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

5. 发明申请

US20160030391A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION 审中-公开
标题翻译：改进认知功能的方法和组合
公开(公告)号：US20160030391A1
公开(公告)日：2016-02-04
申请号：US14776192
申请日：2014-03-14
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： Michela Gallagher , Rebecca Haberman , Ming Teng Koh , Arnold Bakker
IPC分类号： A61K31/4015 , A61K31/13
CPC分类号： A61K31/4015 , A61K31/13 , A61K45/06 , A61K2300/00
摘要： This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A) in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.
摘要翻译：本发明涉及用于治疗与中枢神经系统（CNS）病症相关的认知障碍的方法和组合物。特别涉及使用突触囊泡糖蛋白2A（SV2A）抑制剂与美金刚或其衍生物或类似物联合用于治疗与有需要的受试者相关的认知障碍或需要或受试者的中枢神经系统（CNS）风险，包括但不限于具有年龄相关认知障碍或轻度认知障碍（MCI），遗忘MCI（aMCI），年龄相关记忆障碍（AAMI），年龄相关认知衰退（ARCD），或年龄相关认知衰退痴呆，阿尔茨海默病（AD），前驱性AD，创伤后应激障碍（PTSD），精神分裂症或双相情感障碍，肌萎缩性侧索硬化，癌症相关认知障碍，智力迟钝，帕金森病（PD），孤独症，强迫行为，和物质成瘾。

6. 发明申请

US20140057903A1 METHODS FOR CHARACTERIZING AND TREATING COGNITIVE IMPAIRMENT IN AGING AND DISEASE 审中-公开
标题翻译：用于表征和治疗衰老和疾病中的认知障碍的方法
公开(公告)号：US20140057903A1
公开(公告)日：2014-02-27
申请号：US13939028
申请日：2013-07-10
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： Michela Gallagher , Rebecca Haberman
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K31/5513 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G16B20/00 , G16B40/00
摘要： This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging.
摘要翻译：本发明提供用于鉴定与认知障碍相关的基因并鉴定用于治疗认知障碍的化合物的方法。该方法特别可用于鉴定与老化认知障碍有关的基因和可用于治疗认知障碍的化合物。

7. 发明公开

US20230277501A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION 审中-公开
公开(公告)号：US20230277501A1
公开(公告)日：2023-09-07
申请号：US18107336
申请日：2023-02-08
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： Michela Gallagher , Rebecca Haberman , Ming Teng Koh , Arnold Bakker
IPC分类号： A61K31/4015 , A61P25/28 , A61K31/19 , A61K45/06 , A61B5/00 , C12Q1/6883 , G01N33/68 , G01N33/74 , G09B3/06
CPC分类号： A61K31/4015 , A61P25/28 , A61K31/19 , A61K45/06 , A61B5/4088 , C12Q1/6883 , G01N33/6896 , G01N33/74 , G09B3/06 , C12Q2600/118 , C12Q2600/158 , G01N2333/4703 , G01N2333/575 , G01N2800/2814 , G01N2800/52
摘要： This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

8. 发明申请

US20220218665A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION 有权
公开(公告)号：US20220218665A1
公开(公告)日：2022-07-14
申请号：US17404124
申请日：2021-08-17
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： Michela Gallagher , Rebecca Haberman , Ming Teng Koh
IPC分类号： A61K31/4015 , A61K31/20 , A61K31/19
摘要： This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI).

9. 发明申请

US20150313876A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA 审中-公开
标题翻译：用于治疗精神病药的方法和组合物
公开(公告)号：US20150313876A1
公开(公告)日：2015-11-05
申请号：US14442996
申请日：2013-11-14
申请人： Michela GALLAGHER , THE JOHNS HOPKINS UNIVERSITY
发明人： Michela Gallagher
IPC分类号： A61K31/4015 , A61K45/06
CPC分类号： A61K31/4015 , A61K31/20 , A61K31/407 , A61K31/454 , A61K31/496 , A61K31/519 , A61K31/5513 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and prodrugs thereof. The methods and the compositions can be used for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).
摘要翻译：本发明涉及通过使用突触小泡蛋白2A（SV2A）抑制剂和抗精神病药或其药学上可接受的盐，水合物，溶剂合物，多晶型物和前药的组合来治疗精神分裂症或双相性精神障碍（特别是躁狂症）的方法和组合物其中。方法和组合物可用于治疗与精神分裂症或双相性精神障碍（特别是躁狂症）相关的一种或多种阳性和/或阴性症状以及认知障碍。

10. 发明授权

US10624875B2 Methods and compositions for treating schizophrenia 有权
公开(公告)号：US10624875B2
公开(公告)日：2020-04-21
申请号：US15629314
申请日：2017-06-21
申请人： The Johns Hopkins University
发明人： Michela Gallagher , Ming Teng Koh
IPC分类号： A61K31/4015 , A61K45/06 , A61K31/20 , A61K31/407 , A61K31/454 , A61K31/496 , A61K31/519 , A61K31/5513 , A61K31/554 , A61P25/00 , A61P25/18
CPC分类号： A61K31/4015 , A61K31/20 , A61K31/407 , A61K31/454 , A61K31/496 , A61K31/519 , A61K31/554 , A61K31/5513 , A61K45/06 , A61P25/00 , A61P25/18 , A61K31/4015 , A61K2300/00 , A61K31/20 , A61K2300/00
摘要： The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式